Goodwill (Details)	3 Months Ended								12 Months Ended			6 Months Ended	3 Months Ended		12 Months Ended	45 Months Ended	3 Months Ended
	Dec. 31, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Sep. 30, 2011 USD ($)	Jun. 30, 2011 USD ($)	Mar. 31, 2011 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2012 Lev Pharmaceuticals, Inc USD ($)	Jun. 30, 2012 Lev Pharmaceuticals, Inc Cinryze USD ($)	Oct. 21, 2008 Lev Pharmaceuticals, Inc Cinryze USD ($)	Dec. 31, 2012 Lev Pharmaceuticals, Inc Cinryze Minimum USD ($)	Jun. 30, 2012 Lev Pharmaceuticals, Inc Cinryze Minimum USD ($)	Sep. 30, 2012 DuoCort Pharma AB USD ($)	Sep. 30, 2012 DuoCort Pharma AB SEK	Nov. 15, 2011 DuoCort Pharma AB USD ($)	May 31, 2010 Auralis Limited USD ($)
Goodwill disclosures
Contingent consideration, potential payment per share value														$ 0.50
Contingent consideration, potential cash payment														$ 87,500,000
Sales milestone threshold needed to trigger contingent payment															600,000,000
Actual net product sales	106,490,000	91,004,000	94,639,000	135,800,000	145,575,000	142,956,000	128,808,000	127,035,000	427,933,000	544,374,000	439,012,000					600,000,000
Contingent consideration cash payment												92,300,000
Addition to goodwill													86,300,000
Recognized goodwill on acquisition																			7,264,000	5,851,000
Adjustments to goodwill resulting from recognition of deferred tax assets																	$ 3,500,000	22,800,000
Ownership interest (as a percent)																			100.00%	100.00%